Home > Resources > Whitepapers > Value Added Medicines

Value Added Medicines

The current pool of existing molecules potentially re-positioned, re-formulated or combined with new technological platforms and services might offer therapeutic alternatives and opportunities for patients and health care systems. Even if this concept has been known for many years, no common terminology has been agreed for these products and their full potential value is not always recognised and rewarded, creating a disincentive for further development. In this context, Medicines for Europea established one single terminology for these medicines known as value added medicines, defined as “medicines based on known molecules that address health care needs and deliver relevant improvements for patients, health care professionals and/or payers”.

Spotlight

Cifarma Científica Farmacêutica LTDA.

Cifarma is a genuinely Brazilian company that was born in Santa Luzia (MG). Founded in 1999 in the era of globalization and with the need to combine technology with humanistic values. In 2002 the company inaugurated its new industrial park installed in an area of 100,000 m², in Goiânia (GO), a strategic region for the distribution of its products throughout the country.

OTHER WHITEPAPERS

2020 Prescription Drug List

whitePaper | April 7, 2020

The information in this document is designed to help you understand the prescription drug benefits offered under this plan and to compare these benefits to those offered by other plans. Information contained in this summary is designed to help you compare both the value and scope offormulary benefits.

Alcami Grows Contract Manufacturing and Laboratory Business 20%

whitePaper | February 23, 2023

A period of substantial growth is an exciting time in the life of any company. For those in pharmaceutical contract research, development, or manufacturing.

Determine the right dust collection equipment for tablet press applications

whitePaper | October 13, 2022

Though tablet compression does not generate large volumes of fugitive dust, safe and efficient collection of whatever dust is created by this process is critical. The dust collector linked to the press can contribute to reliable, consistent performance

Access to medicinal products

whitePaper | January 3, 2022

There are many factors that can prevent a patient from being able to obtain the medicine they need, ranging from selective marketing decisions by companies to products being too expensive or pharmacy stock-outs

Introducing EU Annex 1: Understanding the Newest Regulatory Requirements

whitePaper | July 1, 2023

As its title implies, Annex 1 is the European guidance document for good manufacturing practices of medicinal products. As such, it serves as the road map for sterile drug manufacturers to follow in order to arrive at the pathway to the highest level of sterility, assuring that their medicinal drug products deploy operational best practices, are certifiable, and regulatorily safe.

Value Added Medicines